NCT04301752View on ClinicalTrials.gov

Cognitive Impairment and Neuropsychiatric Manifestations of Neurobrucellosis

CompletedOBSERVATIONAL
Enrollment

82

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

January 1, 2020

Study Completion Date

March 1, 2020

Conditions
Brucellosis
Interventions
DIAGNOSTIC_TEST

MoCA

Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were \<26. Maximum score is 30.

Trial Locations (1)

Unknown

Mansoura University Hospital, Al Mansurah

All Listed Sponsors
lead

Mansoura University Hospital

OTHER

NCT04301752 - Cognitive Impairment and Neuropsychiatric Manifestations of Neurobrucellosis | Biotech Hunter | Biotech Hunter